Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jun;6(3):393-395.
doi: 10.21037/tlcr.2017.04.06.

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C Santini  1 , Siddharth Kunte  2 , Alexander Drilon  1   3
Affiliations
Editorial

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C Santini et al. Transl Lung Cancer Res. 2017 Jun.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The authors have no conflicts of interest to declare.

Comment on

References

    1. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103. 10.1038/nrc3205 - DOI - PubMed
    1. Haura EB, Smith MA. Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer. J Clin Oncol 2013;31:4148-50. 10.1200/JCO.2013.50.8234 - DOI - PubMed
    1. Matsubara D, Ishikawa S, Sachiko O, et al. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol 2010;177:2191-204. 10.2353/ajpath.2010.100217 - DOI - PMC - PubMed
    1. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105-14. 10.1200/JCO.2012.47.4189 - DOI - PMC - PubMed
    1. Koeppen H, Yu W, Zha J, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014;20:4488-98. 10.1158/1078-0432.CCR-13-1836 - DOI - PMC - PubMed